Galapagos Genomics and Procter & Gamble Collaborate in Osteoporosis

6/11/2003, 1:30 PM (Source: GlobeNewswire)

Mechelen, Belgium, June 11, 2003 -- Galapagos Genomics, a privately
held functional genomics company, today announced that it has entered
into collaboration with Procter & Gamble in the field of
osteoporosis. Under the terms of the agreement, P&G obtains access
to novel targets that drive bone formation. The targets have been
discovered by Galapagos using its adenovirus based PhenoSelect(TM)
technology and validated in multiple models. P&G will use its
expertise in osteoporosis to further validate the role of these
targets in osteoporosis disease and where appropriate, initiate the
development of novel drugs based on these proteins. Under the terms
of the agreement, Galapagos is eligible for option fees, milestone
payments and royalties on product sales. Financial terms were not
disclosed.

"This deal confirms that Galapagos' PhenoSelect platform is ideally
suited to find novel genes that are key regulators of disease
processes. We are delighted to have P&G as a partner for these
osteoporosis targets," said Onno van de Stolpe, CEO of Galapagos.
"With the disease focus and development expertise of P&G, we are
confident that these targets are in the best hands to be developed
into novel therapeutics for osteoporosis".

"With this collaboration, we are expanding our relationship with
Galapagos. In addition to using their adenoviral technology to
validate our own targets, we now have access to Galapagos' validated
osteogenic targets," said Dr. Larry Games, Procter & Gamble Vice
President, Research and Development, Global Pharmaceuticals. "The
next generation therapeutics in osteoporosis will need to have bone
forming activity, and this is exactly what Galapagos' targets are
aimed at".

Disease background
Osteoporosis is principally a disease of middle age during which
hormone levels essential for maintaining bone density, decline. The
development of osteoporosis is characterized by a clinically
significant reduction in mean bone density due to an increase in bone
resorption. The disease is four times as common in women than men.
The enormous health care costs associated with osteoporosis,
estimated at $15 billion in the USA, are related to the greatly
increased incidence of fractures in osteoporosis patients. Whereas
most current therapies have an anti-resorptive mechanism of action,
agents with bone-forming properties can be identified for future
therapies by identifying targets and molecules with anabolic
functions and actions.

About Galapagos
Galapagos Genomics is a privately held company headquartered in
Mechelen, Belgium. The Company has built a functional genomics
platform using arrayed adenoviruses containing human gene sequences.
It's knock-in PhenoSelect and knock-down SilenceSelect collections
are in an arrayed format that enables high-throughput screening using
cellular assays. Galapagos is using its technology platform for the
discovery and validation of proprietary drug targets and for
partnering with biotechnology and pharmaceutical companies. It's
research programs focus on three disease areas: Alzheimer's disease,
bone diseases and psoriasis. The Company currently employs 94
people, including 22 PhD's, and occupies a 2000 sq.m. research and
production facility in Mechelen, with additional research
laboratories in Leiden, The Netherlands. Galapagos' other partners
include Bayer, Euroscreen, Exelixis, Incyte, Johnson&Johnson,
Organon, Pharmacia, UCB Pharma and Vertex. The shareholders are
Abingworth Management, Apax Partners, Burrill&Company, NIB Capital
Private Equity, Crucell Holland BV (Nasdaq, Euronext: CRXL) and
Tibotec-Virco NV. More information on Galapagos can be found at
www.galapagosgenomics.com. PhenoSelect(TM) and SilenceSelect(TM) are
pending trademarks owned by Galapagos Genomics NV.

About Procter & Gamble
Two billion times a day, P&G brands touch the lives of people around
the world. Some of the nearly 300 P&G brands consumers know and use
with confidence in over 160 countries around the world include:
Pampers®, Tide®, Ariel®, Always®, Whisper®, Pantene®, Bounty®,
Pringles®, Folgers®, Charmin®, Downy®, Lenor®, Iams®, Crest®, Olay®,
and Clairol Nice 'n Easy®. Some of P&G Pharmaceuticals leading
prescription products include Actonel® (risedronate sodium tablets),
Asacol® (mesalamine), and Macrobid® (nitrofurantoin monohydrate
macrocrystals). The P&G community consists of nearly 102,000
employees working in almost 80 countries worldwide. Please visit
www.pg.com for the latest news and in-depth information about P&G
and its brands.


For more information, please contact:
Onno van de Stolpe, CEO
+32 15 342 900
onno@galapagos.be
Copyright GlobeNewswire, Inc. 2016. All rights reserved.
You can register yourself on the website to receive press releases directly via e-mail to your own e-mail account.